Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Buprenorphine clinical trials

Also listed in trial records as Temgesic, Sublocade
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our Canada, Mexico, UK, USA and France registers that name Buprenorphine as an intervention. Synced 13 Nov 2026
5Current trials
4Recruiting now
5Lead sponsors
5Country registers
At a glance

Buprenorphine is named as an intervention in 5 current clinical trials in our Canada, Mexico, UK, USA and France registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Eli Lilly and Company (1). The most-studied condition is Opioid Use Disorder.

Where Buprenorphine is approved

All regulators →

Of the three regulators tracked here, the first to approve Buprenorphine was the US, on 29 Dec 1981. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)
29 Dec 1981
Buprenex
NDA018401 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
20 Nov 2018
Buvidal
EMA product page
First centralised authorisation
CACanada (Health Canada)
27 Sep 1994
Buprenex
Notice of Compliance 5510
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Buprenorphine patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Buprenorphine, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Butrans, Belbuca, Brixadi
  • 23 listed patents; the last listed expires 22 Jun 2038 (US 10646484).
  • Exclusivity M-314: Other exclusivity: updates to the prescribing information based on results of clinical studies, until 21 Feb 2028.
See the Orange Book listing for NDA 021306
Patents and exclusivities above are pooled across 4 applications for this substance.

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Buprenorphine

All medicines →
ENNHS England
£70.3m
3,789,694 items dispensed, Sep 2025 to Aug 2026
-6% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
$1.01bn
1,433,172 prescriptions in 2025 · Sublocade, Brixadi, Belbuca
+32% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Buprenorphine works

All drug targets →
  • Mu opioid receptor agonist Agonist
    Target: OPRM1 opioid receptor mu 1
    ✓ In ChEMBL and the Guide to Pharmacology
  • Kappa opioid receptor agonist Agonist
    Target: OPRK1 opioid receptor kappa 1
    ✓ In ChEMBL and the Guide to Pharmacology
Diseases it has been tested for in clinical trials, by furthest phase
  • Back painPhase 3
  • AnxietyPhase 3
  • Cancer painPhase 3
  • Chronic back painPhase 3
  • Cocaine abusePhase 3
  • Depressive disorderPhase 3
  • Heroin dependencePhase 3
  • Major depressive disorderPhase 3
  • Neonatal abstinence syndromePhase 3
  • Opioid use disorderPhase 3
26 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL511142, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 1670, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Buprenorphine

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Buprenorphine. 1 is current, and 1 of it recommends it for at least some patients.

AppraisalNICE recommendationPublishedStatus
Methadone and buprenorphine for the management of opioid dependence
NICE TA114
Recommended24 Jan 2007Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Buprenorphine

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting480%
  • Active, closed120%

Trials by phase

  • Phase 2240%
  • Phase 3120%
  • Observational120%
  • Phase 4120%
01

Clinical trials of Buprenorphine

5 trials
StudyPhaseStatusLead sponsorRegisters
Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial
NCT07439549 · ClinicalTrials.gov ↗ · Opioid Use Disorder
Phase 4 Recruiting Pouya Azar Canada
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
NCT03646058 · ClinicalTrials.gov ↗ · Suicidal Ideation, Major Depressive Episode
Phase 3 Recruiting Centre Hospitalier Universitaire de Nīmes France
A Study of Brenipatide in Participants With Opioid Use Disorder
NCT07420283 · Opioid Use Disorder
Phase 2 Recruiting Eli Lilly and Company UK, USA, Canada
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT03511118 · ClinicalTrials.gov ↗ · Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Observational Recruiting Duke University Canada, Mexico
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04464980 · ClinicalTrials.gov ↗ · Opioid Use Disorder (OUD)
Phase 2 Active, closed NYU Langone Health Mexico

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Buprenorphine across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

32 single-substance products containing Buprenorphine on the HPRA medicines list.

All 32 Irish products →

Supply shortages

  • Buprenorphin AWD Matrix 70 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
  • Buprenorphin AWD Matrix 70 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
  • Buprenorphin AWD Matrix 70 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
  • Buprenorphin AWD Matrix 52,5 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
  • Buprenorphin AWD Matrix 52,5 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026
  • Buprenorphin AWD Matrix 52,5 Mikrogramm/h Transdermales PflasterGermany (BfArM) · Other reason · 14 Mar 2024 to 18 Dec 2026

+ 5 more German shortage notices.

03

Conditions studied with Buprenorphine

6 conditions
Opioid Use Disorder2Suicidal Ideation1Major Depressive Episode1Lactating Women on Select DOI1Breastfed Infants of Mothers on Select DOI1Opioid Use Disorder (OUD)1
04

Sponsors

lead sponsor per trial
Lead sponsorTrials
Eli Lilly and Company1
Centre Hospitalier Universitaire de Nīmes1
Duke University1
Pouya Azar1
NYU Langone Health1
05

By country register

RegisterTrialsRecruiting
Clinical trials in Canada33
Clinical trials in Mexico21
Clinical trials in UK11
Clinical trials in USA11
Clinical trials in France11

A trial with sites in more than one country appears in each of those registers.

06

Related compounds

07

Questions about Buprenorphine trials

How many clinical trials are testing Buprenorphine?

5 current trials in our Canada, Mexico, UK, USA and France registers name Buprenorphine as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Buprenorphine trials recruiting patients?

Yes. 4 of the 5 trials are recruiting: 3 with sites in Canada, 1 with sites in Mexico, 1 with sites in UK, 1 with sites in USA and 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Buprenorphine clinical trials?

Eli Lilly and Company (1), Centre Hospitalier Universitaire de Nīmes (1), Duke University (1) and Pouya Azar (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Buprenorphine licensed in Ireland?

Yes. The HPRA medicines list includes 32 single-substance products containing Buprenorphine, for example BuTrans 10 micrograms/hour transdermal patch (Mundipharma Pharmaceuticals Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Buprenorphine shortage?

The registers we track list 11 entries for Buprenorphine: 11 German notices. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Buprenorphine works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Buprenorphine works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Buprenorphine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.